A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Age \> 18 years 2. Histologically confirmed Stage IV non-squamous NSCLC or clear cell RCC 3. NSCLC-specific criterion: Best tumor response (by iRECIST) as Stable Disease 4. NSCLC-specific criterion: PD-L1 expression \> 50% 5. ECOG Performance Status = 0-1 6. Negative stool PCR test for Akkermansia 7. At least one measurable lesion per iRECIST 8. Hemoglobin ≥ 100 g/L 9. Albumin \> 35 g/L 10. Signed informed consent Exclusion Criteria: 1. Symptomatic brain metastases 2. AST or ALT \> 5 x ULN 3. Calculated creatinine clearance \< 45 ml/min 4. Auto-immune diseases requiring systemic therapy 5. Immunosuppressive therapy (\> 10 mg prednisone/day equivalent) 6. Radiotherapy (\> 30 Gy) to the lung(s) within 6 months of signed informed consent 7. Active infection 8. Co-morbidities that may increase the risk of treatment-related adverse events 9. Pregnancy 10. Inability to comply with protocol-specific assessments